Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Bentley Pharmaceuticals to Host First Quarter 2006 Conference Call and Webcast on Wednesday May 10, 2006.


EXETER, N.H. -- Bentley Pharmaceuticals, Inc. (NYSE NYSE

See: New York Stock Exchange
: BNT BNT Bentley Pharmaceuticals, Inc. (stock symbol)
BNT Boston Naming Test (psychology)
BNT Bermuda National Trust
BNT Bulgarian National TV
BNT Broadband Network Termination
BNT Binary File Transfer
), a specialty pharmaceutical and drug delivery company, today announced that management will host a conference call to discuss first quarter 2006 results and provide a business update on Wednesday, May 10, 2006, at 10:00 A.M. EDT EDT
abbr.
Eastern Daylight Time


EDT Eastern Daylight Time

EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York

EDT 
. Bentley will release results for the three months ended March 31, 2006, before the open of the market on that day.

To participate on the live call, please dial (888) 332-7254 from the U.S. and Canada or, for international callers, please dial (973) 582-2856 (access code 7347553), approximately 10 minutes prior to the scheduled start time. A telephone replay will be available for 30 days by dialing (877) 519-4471 from the U.S. and Canada or (973) 341-3080 for international callers (please reference reservation number 7347553). The conference call will also be broadcast live on the Internet and may be accessed via Bentley's web site, www.bentleypharm.com. Please go to the Company's web site approximately 10 minutes prior to the scheduled start time to register. A replay of the conference will also be available on Bentley's web site for 30 days.

Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and pharmaceutical products. Bentley's proprietary drug technologies enhance or facilitate the absorption of pharmaceutical compounds across various membranes. Bentley also manufactures a growing portfolio of generic and branded pharmaceuticals in Europe for the treatment of cardiovascular cardiovascular /car·dio·vas·cu·lar/ (-vas´ku-ler) pertaining to the heart and blood vessels.

car·di·o·vas·cu·lar
adj.
Abbr.
, gastrointestinal gastrointestinal /gas·tro·in·tes·ti·nal/ (-in-tes´ti-n'l) pertaining to or communicating with the stomach and intestine.

gas·tro·in·tes·ti·nal
adj.
Abbr.
, infectious and neurological diseases Noun 1. neurological disease - a disorder of the nervous system
nervous disorder, neurological disorder

disorder, upset - a physical condition in which there is a disturbance of normal functioning; "the doctor prescribed some medicine for the disorder";
 through its subsidiary, Laboratorios Belmac, and markets these pharmaceutical products through its subsidiaries, Laboratorios Belmac, Laboratorios Davur, Laboratorios Rimafar and Bentley Pharmaceuticals Ireland; and manufactures and markets active pharmaceutical ingredients through its subsidiary, Bentley API (Application Programming Interface) A language and message format used by an application program to communicate with the operating system or some other control program such as a database management system (DBMS) or communications protocol. .

Copies of Bentley Pharmaceuticals' press releases and other information may be obtained through Bentley's web site at www.bentleypharm.com.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:May 3, 2006
Words:299
Previous Article:Survey Finds No Awareness of Common Genetic Disease; More than 9 out of 10 Jewish Americans Unaware of Gaucher Disease, Which Can Be Debilitating and...
Next Article:A.D.A.M., Inc. Reports Financial Results for First Quarter 2006; Net Income of $0.07 Per Share, Healthcare Licensing Revenues Increase 18%.
Topics:



Related Articles
Bentley Pharmaceuticals to Release First Quarter 2005 Earnings after the Market Closes on Wednesday, May 4, 2005 and Host Conference Call and Webcast...
Bentley Pharmaceuticals To Release Second Quarter 2005 Earnings after the Market Closes on Wednesday, August 3, 2005 and Host Conference Call and...
Bentley Pharmaceuticals to Present at the Citigroup 2006 Healthcare Conference on March 1, 2006.
Bentley Pharmaceuticals to Report Fourth Quarter and Full-Year 2005 Financial Results on March 8, 2006.
Bentley Pharmaceuticals to Host Second Quarter 2006 Conference Call and Webcast on Thursday August 3, 2006.
Bentley Pharmaceuticals Reports Second Quarter 2006 Results; Diluted EPS Totaled $0.12; Revenues Grew 17% to a Record $29.0 Million.
Bentley Pharmaceuticals to Host Third Quarter 2006 Conference Call and Webcast on Thursday, November 2, 2006.
Bentley Pharmaceuticals Reports Third Quarter 2006 Results.
Bentley Pharmaceuticals to Announce Fourth Quarter and Full-Year 2006 Financial Results and Conduct a Conference Call on March 1, 2007.
Bentley Pharmaceuticals Reports $0.10 Diluted EPS on Record Revenues of $31.4 Million in the First Quarter of 2007.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles